An eight-week gap between the first and second doses of the Pfizer/BioNTech Covid-19 vaccine is a "sweet spot" when it comes to generating strong immune response while protecting a population against the Delta variant of coronavirus, scientists have said.
In a new study, funded by the UK's Department of Health and Social Care (DHSC), researchers found that when compared to a four-week gap, a ten-week interval between the doses produces higher antibody levels, as well as a higher proportion of a group of infection-fighting cells in the body known as "helper" T cells.
At the start of the UK's second wave of the Covid-19 epidemic, the Joint Committee on Vaccination and Immunisation (JCVI) made a decision to recommend a 12-week gap between two